The European Association of Cardiovascular Imaging/Heart Failure Association Cardiac Oncology Toxicity Registry: long-term benefits for breast cancer treatment

Future Oncol. 2015;11(20):2791-4. doi: 10.2217/fon.15.227. Epub 2015 Sep 7.

Authors

Guy Jerusalem¹, Marie Moonen², Pierre Freres¹, Patrizio Lancellotti²

Affiliations

¹ Medical Oncology, CHU Sart Tilman Liege & Liege University, Domaine Universitaire du Sart Tilman, B35, 4000 Liege, Belgium.
² University of Liège Hospital, GIGA Cardiovascular Sciences, Cardio-Oncology Clinic Unit, CHU Sart Tilman Liege & Liege University, Domaine Universitaire du Sart Tilman, B35, 4000 Liege, Belgium.

PMID: 26344798
DOI: 10.2217/fon.15.227

No abstract available

Keywords: anthracyclines; breast cancer; cardiac toxicity; cardio-oncology; monitoring; trastuzumab.

Publication types

Editorial

MeSH terms

Antineoplastic Agents / adverse effects*
Breast Neoplasms / therapy*
Cardiotoxicity*
Europe
Female
Humans
Radiotherapy / adverse effects*
Registries*
Risk Factors

Substances

Antineoplastic Agents